Mesenchymal Terapia con cellule staminali,COVID 19
Astratto
“COVID 19” è la parola che certamente non viene dimenticata da tutti coloro che vivono nella prima metà del XXI secolo. COVID 19, come una pandemia, ha portato molti ricercatori provenienti da diversi ambiti biomedici a trovare soluzioni o trattamenti per gestire la pandemia. Tuttavia, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, cellule staminali mesenchimali (MSC)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recentemente, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in terapia con cellule staminali. in questo studio, we considered this new approach to improve patient’s immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. Tuttavia, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.
